Industry
Drug Manufacturers - General
Scilex Holding Company, a biopharmaceutical company, focuses on developing and commercializing non-opioid management products for the treatment of acute and chronic pain. Its commercial product is ZTlido 1.8%, a prescription lidocaine topical product for the relief of neuropathic pain related with post-herpetic neuralgia, which is a form of post-shingles nerve pain. It also offers SP-102, a viscous gel formulation of corticosteroid for epidural injections that is in a Phase III clinical trial to treat lumbosacral radicular pain; SP-103, which is in Phase II clinical trail for the treatment of low back pain; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation that has completed Phase I clinical trial for the treatment of fibromyalgia. The company is headquartered in Palo Alto, California. Scilex Holding Company is a subsidiary of Sorrento Therapeutics, Inc.
Loading...
Open
0.52
Mkt cap
97M
Volume
1.2M
High
0.52
P/E Ratio
-0.40
52-wk high
2.63
Low
0.48
Div yield
N/A
52-wk low
0.46
Portfolio Pulse from
November 22, 2024 | 11:15 am
Portfolio Pulse from
November 06, 2024 | 5:45 pm
Portfolio Pulse from Benzinga Newsdesk
October 30, 2024 | 10:20 am
Portfolio Pulse from Benzinga Newsdesk
October 21, 2024 | 10:29 am
Portfolio Pulse from Vandana Singh
October 16, 2024 | 7:07 pm
Portfolio Pulse from Benzinga Newsdesk
October 16, 2024 | 1:05 pm
Portfolio Pulse from Benzinga Newsdesk
October 16, 2024 | 11:04 am
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.